Search results
Refer to the recommended dosing and administration information for each indication when prescribing ELIQUIS® to patients. See Indications and Important Safety Information, including Boxed WARNINGS.
- Real-World Evidence | ELIQUIS® (apixaban) for HCPs
See Indications and Important Safety Information, including...
- Real-World Evidence | ELIQUIS® (apixaban) for HCPs
See Indications and Important Safety Information, including Boxed WARNINGS. 1; 2; 3; ... (CYP3A4) increase exposure to apixaban and increase the risk of bleeding. For patients receiving ELIQUIS doses of 5 mg or 10 mg twice daily, reduce the dose of ELIQUIS by 50% when ELIQUIS is coadministered with drugs that are combined P-gp and strong CYP3A4 ...
Produkt Eliquis jest przeciwwskazany u dorosłych pacjentów z chorobami wątroby przebiegającymi z koagulopatią i klinicznie istotnym ryzykiem krwawienia (patrz punkt 4.3). Nie zaleca się stosowania produktu Eliquis u pacjentów z ciężkimi zaburzeniami czynności wątroby (patrz punkty 4.4 i 5.2).
Dawkowanie. Zalecana dawka produktu ELIQUIS to 2,5 mg, przyjmowana doustnie, dwa razy na dobę. Pierwszą dawkę należy zażyć 12-24 godziny po zabiegu chirurgicznym.
ELIQUIS® (apixaban) dosing information for patients with deep vein thrombosis (DVT) and pulmonary embolism (PE). Guidance for healthcare professionals in Ireland.
31 lip 2024 · The recommended dose of ELIQUIS is 2.5 mg twice daily in patients with at least two of the following characteristics: •. age greater than or equal to 80 years. •. body weight less than or equal to 60 kg. •. serum creatinine greater than or equal to 1.5 mg/dL.
ELIQUIS is indicated for the treatment of DVT and PE, and to reduce the risk of recurrent DVT and PE following initial therapy. Please see U.S. FULL PRESCRIBING INFORMATION, including Boxed WARNINGS, and MEDICATION GUIDE. ELIQUIS is available in 2.5 mg and 5 mg tablets.
